Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

被引:5
|
作者
Carr, Rebecca A. [1 ]
Hsu, Meier [2 ]
Harrington, Caitlin A. [1 ]
Tan, Kay See [2 ]
Bains, Manjit S. [1 ]
Bott, Matthew J. [1 ]
Ilson, David H. [3 ]
Isbell, James M. [1 ]
Janjigian, Yelena Y. [3 ]
Maron, Steven B. [3 ]
Park, Bernard J. [1 ]
Rusch, Valerie W. [1 ]
Sihag, Smita [1 ]
Wu, Abraham J. [4 ]
Jones, David R. [1 ]
Ku, Geoffrey Y. [3 ]
Molena, Daniela [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
CROSS regimen; esophageal adenocarcinoma; FOLFOX; induction; positron emission tomography-directed chemoradiation; COMPLETE PATHOLOGICAL RESPONSE; ESOPHAGOGASTRIC JUNCTION; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; TUMOR-REGRESSION; SURVIVAL; CHEMOTHERAPY; CANCER; CARCINOMA; THERAPY;
D O I
10.1097/SLA.0000000000005163
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC. Summary of Background Data: nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy. Methods: We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with >= 90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression. Results: In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group. Conclusions: Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.
引用
收藏
页码:E538 / E544
页数:7
相关论文
共 50 条
  • [21] Definitive chemoradiation in the management of locally advanced esophageal cancer
    Suntharalingam, Mohan
    SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (01) : 22 - 28
  • [23] Neoadjuvant chemoradiation treatment of locally advanced adenocarcinoma of the duodenum
    Kluger, Y
    Soffer, D
    Sorid, D
    Michowitz, M
    Schreiber, L
    Klausner, JY
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2000, 2 (12): : 947 - 948
  • [24] FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma
    Rouf, R.
    Ku, G.
    Cowzer, D.
    Harrington, C.
    Maron, S.
    Janjigian, Y.
    Ilson, D. H.
    Molena, D.
    Sihag, S.
    Hajj, C.
    Crane, C. H.
    Wu, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E167 - E167
  • [25] Retrospective analysis of concurrent chemoradiation with carboplatin/paclitaxel vs FOLFOX in esophageal adenocarcinoma
    Adler, J. A.
    Patell, K.
    Naleid, N.
    Rao, R.
    Elshami, M.
    Patel, R.
    Kaur, J.
    Guzik, G.
    Karia, R.
    Mohamed, A.
    Bajor, D.
    Conces, M. L.
    Lumish, M.
    Ocuin, L.
    Henke, L.
    Mahipal, A.
    Chakrabarti, S.
    Selfridge, J. E. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S166 - S166
  • [26] PET response to chemoradiation for locally advanced rectal cancer
    Joon, D. Lim
    Mak, D.
    Khoo, V.
    Wada, M.
    Feigen, M.
    Joon, M. Lim
    See, A.
    Chao, M.
    Rolfo, A.
    Rykers, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S295 - S295
  • [27] Can PET CT predict response in locally advanced rectal cancer patients treated with induction FOLFOX?
    Gunduz, Seyda
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    Arslan, Deniz
    Tatli, Ali Murat
    Uysal, Mukremin
    Savas, Burhan
    Ozdogan, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary? Discussion
    Stiles, Brendon M.
    Liou, Douglas Z.
    Swanson, S.
    Nason, Katie S.
    Watson, Thomas J.
    Hofstetter, Wayne L.
    Lebenthal, A.
    Egan, Thomas M.
    Riyadh
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06): : 2705 - 2707
  • [29] Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX)
    Lledo, G.
    Michel, P.
    Dahan, L.
    Mineur, L.
    Galais, M.
    Dupuis, O.
    Abdiche, S.
    Jovenin, N.
    Chibaudel, B.
    De Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [30] Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).
    Dahan, L.
    Chibaudel, B.
    Di Fiore, F.
    Artru, P.
    Mineur, L.
    Galais, M.
    Dupuis, O.
    Blondin, V.
    Abdiche, S.
    Attia, M.
    De Gramont, A.
    Lledo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)